The dual health and economic crisis resulting from COVID-19 has brought into sharp focus the importance of ethical business conduct. Small and medium enterprises (SMEs) in the medical device and biopharmaceutical sectors have been significantly impacted, during a time when they are being called upon for major action.
Today, IFPMA joined hundreds of diverse stakeholders from more than 30 economies spanning the Asia-Pacific and beyond in a shared commitment to solidify and grow the world’s largest public-private, multi-sectoral partnership in the advancement of business ethics in the medical device and biopharmaceutical sectors, through Vision 2025.
The 2018 APEC Business Ethics for SMEs Forum brought together key players from the medical device industry in some of the world’s most important economies in Tokyo. Read More at http://apisag.cl/